Cerus Announces Schedule of Presentations at the 2017 AABB Annual Meeting
02 October 2017 - 11:30PM
Business Wire
Cerus Corporation (NASDAQ:CERS) announced today its schedule of
key events at the AABB (formerly known as the American Association
of Blood Banks) Annual Meeting to be held October 7-10 in San
Diego, California. Cerus will be presenting the latest clinical
data while blood banks and hospitals will be publishing results
from their own user experience.
Company representatives from Cerus will also be in the
exhibition area at booth 1910.
The AABB Annual Meeting is the largest blood banking conference
of the year globally and scientists and clinicians from around the
world will be attending to hear the latest developments in the
industry.
“We are looking forward to AABB and sharing with the blood
banking community the latest clinical data supporting the use of
INTERCEPT to treat blood components,” said Dr. Richard Benjamin,
Cerus’ chief medical officer.
“Between Cerus and our scientific collaborators, we will have 19
abstract presentations including three oral abstracts. The
abstracts this year cover a broad spectrum of topics including
platelets, plasma, red blood cells, whole blood, and emerging
pathogens.
In addition, this year at AABB, we will have our first
presentation related to our cryoprecipitate initiative. The
abstract shows that pathogen reduced cryo can be processed from
various plasma sources and can be stored at room temperature for 5
days,” Benjamin continued.
A full list of abstracts can be viewed at
https://intercept-usa.com/aabb17.
SCHEDULE OF SESSIONS OF INTEREST
(listed chronologically):
Sunday, October 8 2:00 - 3:30 pm - 0224-S TTD
II-Pathogen Reduced Platelets: Implementation Considerations,
Convention Center - 20A Monday, October 9 2:00 – 2:15
pm – C43-A03F: Compatibility of Apheresis Platelet Collections with
Pathogen Reduction While Maintaining Current Split Rates,
Convention Center – 29A 5:15 – 5:30 pm – C60-A03J: Robust
Inactivation of Mayaro Virus in Platelet Concentrates and Red Blood
Cells Using Nucleic Acid Targeting Pathogen Reduction Technologies
(PRT), Convention Center - 25AB Tuesday, October 10
7:00 – 8:15 am – Cerus Presents
“Experiences in Implementing Pathogen Reduction – From Maintaining
Split Rates at the Blood Center to Treating Patients at the
Hospital, Convention Center – 29A
2:30 – 2:45 pm – C92-A04C: Hemovigilance Monitoring of Platelet
Septic Transfusion Reactions (STR) after Treatment with INTERCEPTTM
Pathogen Reduction or Large Volume, Delayed Bact/ALERTTM Bacterial
Culture Screening, Convention Center – 30ABC
ABOUT CERUS
Cerus Corporation is a biomedical products company focused in
the field of blood transfusion safety. The INTERCEPT Blood System
is designed to reduce the risk of transfusion-transmitted
infections by inactivating a broad range of pathogens such as
viruses, bacteria and parasites that may be present in donated
blood. The nucleic acid targeting mechanism of action of the
INTERCEPT treatment is designed to inactivate established
transfusion threats, such as hepatitis B and C, HIV, West Nile
virus and bacteria, as well as emerging pathogens such as
chikungunya, malaria and dengue. Cerus currently markets and sells
the INTERCEPT Blood System for both platelets and plasma in the
United States, Europe, the Commonwealth of Independent States, the
Middle East and selected countries in other regions around the
world. The INTERCEPT Red Blood Cell system is in clinical
development. See http://www.cerus.com for information about
Cerus.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus
Corporation.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171002005354/en/
Investor Contact:Cerus CorporationTim Lee, 925-288-6137Investor
Relations DirectororMedia Contact:W20 CommunicationsDan
Boyledan@boylepr.com
Cerus (NASDAQ:CERS)
Historical Stock Chart
From Apr 2024 to May 2024
Cerus (NASDAQ:CERS)
Historical Stock Chart
From May 2023 to May 2024